Motley Fool has a good article/comment out on ICPT 13 hrs ago as follows:
"an absolute mound of data to take in during a single day and is a reason why I'm not shocked that Intercept's share price was all over the map today. What's really important here is that OCA looks great as a potential new therapy for primary bilary cirrhosis, and the concerns about increased lipid levels in its NASH trial appear to be statistically insignificant relative to the placebo group. While I would urge investors to be cautious given that with Intercept's share price has risen so much already, this update would suggest that OCA remains on track to possibly become a blockbuster therapy."
I think the price targets recently given as $700 to $800 are reasonable.
consider the source of this article-----just pure babble with no direction like-When is product launch, what is 1st thru 5th year pro-forma's, earning expectation----just standard SOP's to use to judge if this company is worth 17 billion at $ 700 per share or 700 million----more than likely 700 million and that is a stretch
motley fool are poor stewards of information they throw it around like a Navy cook tosses chili